We’re heading to #CAP2024 in Las Vegas, October 19-22! Let’s connect! Schedule a meeting with our team to explore how AISight IMS transforms pathology workflows and enhances case management for improved efficiency. Visit us at booth #406 to see how AISight provides seamless access to embedded AI algorithms, helping pathologists make efficient and reproducible assessments. 📅 Register for a demo: https://lnkd.in/g97kHdMr #CAP #pathai #digitalpathology #aipathology #aiheathcare #anatomicpathology #imagementmanagementsystem AISight is for research use only. Not for use in diagnostic procedures.
PathAI
Software Development
Boston, Massachusetts 56,913 followers
Improving patient outcomes with AI-powered pathology.
About us
PathAI's mission is to improve patient outcomes with AI-powered pathology. Our platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine learning. We are a company of diverse employees with a wide range of backgrounds and experiences. Our world class team is passionate about solving challenging problems and making a huge impact. Our office is located in the heart of Fenway. PathAI was recently voted one of BBJ's Best Places to Work!
- Website
-
http://www.pathai.com
External link for PathAI
- Industry
- Software Development
- Company size
- 501-1,000 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2016
- Specialties
- artificial intelligence, pathology, digital pathology, oncology, immuno-oncology, auto immune disease, neurodegenerative disease, companion diagnostics, precision medicine, R&D, computational pathology, deep learning, software engineering, AI, Machine Learning, IBD, cancer research, oncology research, Drug Development, CRO , Clinical development, healthtech, and Artificial Intelligence
Locations
-
Primary
1325 Boylston St
Suite 10000
Boston, Massachusetts 02215, US
-
3495 Hacks Cross Rd
Memphis, Tennessee 38125, US
Employees at PathAI
Updates
-
🌐 PathAI is excited to announce a new #partnership with the Crohn's & Colitis Foundation. The collaboration will empower academic and #biopharmaceutical researchers to unlock insights into Inflammatory Bowel Disease (IBD) through the unique combination of the well-characterized multi-modal clinical & molecular data from the Crohn’s & Colitis Foundation’s #IBD Plexus dataset, and quantitative #histopathology data derived from PathAI’s suite of proprietary algorithms in IBD. The partnership fuels our mission to transform #drugdevelopment and patient outcomes in IBD with AI-powered #pathology. Link to press release: https://lnkd.in/eVH8RxVn #digitalpathology #AI #inflammatoryboweldisease #IBD #drugdiscovery #biomarkers #RWD #RealWorldData #AIPathology #biotech #genomics #BigData #healthtech
-
Upcoming Event: Join Christina Jayson, Ph.D. at #UEGWeek for her presentation on “AI-powered histology in Inflammatory Bowel Disease: deeper insights for #biomarker discovery and drug development” and to see a #casestudy from our UEG ePoster with leaders in the #IBD space. 🗓️ When: Monday, October 14, 2024 ⌚ Time: 12:30-13:00 & 15:30-16:00 📍 Where: Innovation Hub #2 Stop by our booth at the Innovation Hub to meet our team, see live demos of IBD Explore™ and AIM HI-UC™ (#UlcerativeColitis), and learn more about vertically integrated #digitalpathology solutions & services across the #drugdevelopment lifecycle. Schedule a meeting with us: https://lnkd.in/eTVsBzUN IBD Explore™ and AIM HI-UC™ is for research use only. Not for use in diagnostic procedures. #biotech #pathology #AIPathology #PrecisionMedicine #biotechnology #UEG2024 #UEG
-
Quest Diagnostics recently published a #whitepaper titled “Pathology in the era of precision medicine,” which highlights the power of AI and big data in the evolving practice of pathology for #diagnostics and #drugdevelopment. They also discuss the role of digital and computational pathology #collaborations on this journey, like the one with PathAI. Learn more: https://lnkd.in/ddeQcZNH #pathology #digitalpathology #AI #precisionmedicine #biotech #healthtech
-
Join Darshit Makawana for his session on #AI and #ClinicalTrials today #ASQChicagoSummit2024
Come join my session on AI Product Development Process at ASQ Innovate For Excellence Summit-Chicago: Medical Life Sciences today at 3:15 PM! PathAI #ASQChicagoSummit2024
-
🎙️ In the inaugural episode of Baringa’s Pharmaceutical and Life Sciences Podcast, Baringa's expert Joshua Elliott sits down with Eric Walk MD, FCAP, Chief Medical Officer at PathAI, to explore the essential role of #strategicpartnerships between digital/AI and #biopharma organizations in shaping the future of #precisionmedicine. 🔍 Discover how to anticipate and prevent common challenges in your strategic #partnerships. 🎧 Listen here: https://lnkd.in/eF3KMQPd #biotech #pathology #digitalpathology #partnership #podcast
-
Meet the PathAI team at #OCT SoCal and learn more about #AIPathology solutions to fuel your #oncology #IBD and #LiverDisease research and #drugdevelopment!
Improving Patient Outcomes with AI-Powered Pathology *Hepatology*GI*Oncology Improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians.
Attending OCT SoCal? Come say "hi" and learn about advances in digital pathology and AI.
-
A team of PathAI scientists including Hanna Pulaski, Neel Patel, Hypatia Hou, and Andrew Beck have recently published a new study titled “Validation of a whole slide image management system for metabolic-associated steatohepatitis for #clinicaltrials” in the Journal of #Pathology: Clinical Research. 📝 Read the publication: https://lnkd.in/e3J4A3hw Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global population, and metabolic-associated steatohepatitis (MASH) is now a leading cause of liver transplants. In clinical trials for MASLD #drugdevelopment, glass slides manually read by a pathologist are the gold standard for assessing of #liver #biopsy specimens. However, the need for shipping physical slides from central laboratories to study pathologists risks physical damage to the slides and can result in a slow process. Slide assessment using #digitalpathology may be an accurate and efficient alternative to manual glass slides for evaluating MASH in clinical trials and further addresses key challenges such as endpoint enrollment. Our study demonstrates that the use of digital images on the AISight® Clinical Trials platform yields results equivalent to the use of glass slides for evaluating disease activity in steatohepatitis, streamlining pathologist evaluations and reducing logistical hurdles, thus making #digitalpathology a promising approach for future #clinicaltrials. Learn more about AISight® for #clinicaltrials: https://lnkd.in/eGHH7iFT AISight® is for research use only. Not for use in diagnostic procedures. #AIPathology #biotech #healthtech
-
We’re headed to Vienna, Austria this October for #UEGWeek! Visit us in the innovation hub and request a meeting with us at the upcoming conference to discuss the utilization of #AIPathology for comprehensive and quantitative insights for #IBD & #UlcerativeColitis research. View our upcoming event: https://lnkd.in/eTVsBzUN #pathology #digitalpathology #UEG2024 #biotech #AI #healthtech #biotech #healthcare
-
PathAI is proud to be a sponsor of the Friends of Cancer Research 28th Annual Cancer Leadership Awards. Congratulations to this year’s award recipients for their inspiring service to science, research, patient advocacy, and public policy. We look forward to continuing our collaboration with Friends and peers to spearhead groundbreaking science and accelerate policy change through the Digital PATH Project and other initiatives. Learn more: https://lnkd.in/eqH_bh3W #digitalpathology #innovation #science #research #policy